JPRN-UMIN000002577尚未招募2 期
Effect of Zoledronic acid for Stage D2 hormone-sensitive prostate cancer patients. - Effect of Zoledronic acid for Stage D2 hormone-sensitive prostate cancer patients.
Department of Urology, Keio University School of Medicine0 个研究点目标入组 96 人开始时间: 2009年10月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 85years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1.CCr < 30mL/min by calculation of Codkcroft Gault equation. 2. Another cancer that requires treatment 3. Patients coexisting psychiatric disease or neurological symptom 4. Patients with continuous systematic treatment with steroids 5. Participation in the present study is considered inappropriate by a Clinical Investigator
研究者
相似试验
已完成
2 期
Additive effect of zoledronic acid on hormone-sensitive prostate cancer patients with bone metastasis treated by hormonal therapy: a prospective, multicenter studyProstate cancerJPRN-UMIN000010765Department of Urology, Saitama Medical Center, Saitama Medical University100
已完成
2 期
Phase II study of zoledronic acid concomitant with androgen deprivation therapy for patients with treatment-naive bone-metastatic prostate cancerProstate cancerJPRN-UMIN000007548Kinki University52
已完成
不适用
Zoledronic acid injection prevents bone loss in spinal cord injury patientsCTRI/2018/03/012408Dr Satyaranjan Sethi60
已完成
Unknown
A new study to minimise the side effects of rapid maxillary expansioSide effects of rapid maxillary expansion (RME) on dental and buccal alveolar bone changesOral HealthISRCTN16744226Damascus University32
进行中（未招募）
1 期
The Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis ImperfectaOsteogenesis imperfectaEUCTR2011-002811-27-DKBente Langdahl, consultant, ass. professor, PhD, DMSc80